Description: PharmaEssentia Corporation engages in the research, development, production, and sale of therapeutic products for the treatment of human diseases in Taiwan and internationally. Its products include BESREMi (ropeginterferon alfa-2b) that is used for the treatment of chronic myelogenous leukemia, chronic neutrophilic leukemia, primary myelofibrosis, polycythemia vera, essential thrombocythemia, and hepatitis B and C; and Anti-PD-1 antibody for the treatment of liver cancer. The company also licensed to develop Oraxol for the treatment of breast, gastric, gastro-esophageal, and esophageal cancer; and KX01 for the treatment of psoriasis and actinic keratosis. It also focuses on the drug research and development programs in the areas of hematology, infectious disease, oncology, and dermatology. PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.
Home Page: www.pharmaessentia.com
No. 3, Park Street
Taipei,
115
Taiwan
Phone:
886 2 2655 7688
Officers
| Name | Title |
|---|---|
| Dr. Ching-Leou Teng Ph.D. | Chairman & Chief Pharmaceutical Officer |
| Mr. Ko-Chung Lin Ph.D. | Founder, CEO, Chief Strategy Officer & Director |
| Mr. Chan-Kou Hwang | Pres, GM & Director |
| Ms. Snow Chang | Accounting Mang. & Sr. Mang. of Fin. |
| Mr. Samuel Lin | VP and Head of Bus. Operations & Strategy |
| Ms. Ling Lin Lih | Chief Scientific Officer |
| Ms. Rachel Lipsitz | VP and Head of Corp. Communications & Advocacy |
| Mr. Roddy Mcilwain | Sr. VP and Head of Sales & Marketing |
| Ms. Anjana Pursnani | Sr. VP & Head of People |
| Dr. Albert Qin M.D., Ph.D. | Chief Medical Officer |
Exchange: TWO
Country: TW
Currency: New Taiwan Dollar (NT$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 29.3131 |
| Price-to-Sales TTM: | 64.5321 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |